Shionogi & Co., Ltd.
Notice Regarding Revision of Dividend Forecast (Increase) for the Fiscal Year Ending March 2026
The year-end dividend forecast for the fiscal year ending March 2026 was revised upward by 5 yen per share to 38 yen, with the annual dividend reaching 71 yen, marking the 14th consecutive increase.
Key Figures
- Year-end Dividend Forecast: 38.00 yen (increase of 5 yen from previous forecast)
- Annual Dividend Forecast: 71.00 yen (increase of 10 yen from last fiscal year's 61.00 yen)
- 14th consecutive dividend increase planned
AI要約
Details of Dividend Forecast Revision
Shionogi & Co., Ltd. has revised its year-end dividend forecast for the fiscal year ending March 2026 from 33 yen per share to 38 yen, a 5 yen increase, and adjusted the annual dividend forecast to 71 yen. This marks the 14th consecutive dividend increase. The amounts are stated on a post-stock split (1:3) basis and form part of the dividend policy under the medium-term management plan STS2030 Revision, which aims for a dividend on equity (DOE) of 4% or higher.
Background of the Dividend Increase and Outlook
The dividend increase is backed by growth in the HIV business, domestic and overseas business investments, and business foundation strengthening through M&A, contributing to the expansion of the earnings base. Especially, the penetration of long-acting injectable formulations in the HIV field and progress in new drug development contribute to earnings stability. Based on these factors, the company aims to maximize corporate value and optimize shareholder returns, striving for stable dividend growth.
Shionogi & Co., Ltd.
Company overview · Stock price · Financial data · All IR
